Marketing-authorisation holder · United States
Genetix Biotherapeutics Inc.
3 medicines in 1 country, as authorisation holder.
Medicines
Every medicine in the registers under its name, current ones first.
3 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| LYFGENIA1.7-20x10^6CELL/ML · Suspension | Lovotibeglogene autotemcel | United States | Marketed | 2023 |
| Skysona2-30 10^6 cell/ml · Injection | Elivaldogene autotemcel | United States | Marketed | 2022 |
| Zynteglo1.7-20 x 10^6cell/ml · For Injection | Betibeglogene autotemcel | United States | Marketed | 2022 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 3 | 3 | 0 | CompaniesAll medicines |
Top substances
The active substances in most of its medicines.